DA-302168S clinical trials
Also written DA-302168S.
How each study uses DA-302168S is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the DA-302168S studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- DA-302168S
- 6
Studies by the year they started
7 studies that test it; most in 2026 (4)
| Year | Studies |
|---|---|
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 1 in phase 3
Studies that test DA-302168S, phase 3 first.
- Jul 2027A Study of DA-302168S in Participants With Overweight/ObesityPhase 3 · Chendu DIAO Pharmaceutical Group CO., LTD.
- Dec 2026Mass Balance Study of [14C]DA-302168S in Healthy Chinese Adult Male ParticipantsPhase 1 · Chendu DIAO Pharmaceutical Group CO., LTD.
- Apr 2027Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic FunctionPhase 1 · Chendu DIAO Pharmaceutical Group CO., LTD.
- Oct 2027A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 DiabetesPhase 2 · Chendu DIAO Pharmaceutical Group CO., LTD.
Studies
Open first, then newest update. How each study uses DA-302168S is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Mass Balance Study of [14C]DA-302168S in Healthy Chinese Adult Male ParticipantsNot yet recruitingPhase 1Chendu DIAO Pharmaceutical Group CO., LTD.NCT07857265Written as [14C] DA-302168S
- Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic FunctionNot yet recruitingPhase 1Chendu DIAO Pharmaceutical Group CO., LTD.NCT07877038Written as DA-302168S
- A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 DiabetesNot yet recruitingPhase 2Chendu DIAO Pharmaceutical Group CO., LTD.NCT07755150Written as DA-302168S
- A Study of DA-302168S in Participants With Overweight/ObesityRecruitingPhase 3Chendu DIAO Pharmaceutical Group CO., LTD.NCT07629544Written as DA-302168S
- A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese SubjectsCompletedPhase 2Chendu DIAO Pharmaceutical Group CO., LTD.NCT06953063Written as DA-302168S
- A Study Evulating DA-302168S Tablets in Overweight/Obese SubjectsCompletedPhase 1Chendu DIAO Pharmaceutical Group CO., LTD.NCT06541730Written as DA-302168S
- Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of DA-302168S TabletsCompletedPhase 1Chendu DIAO Pharmaceutical Group CO., LTD.NCT06534320Written as DA-302168S
What changed recently
From the registry's own updates since Oct 18, 2026.